Use of apomorphine in Parkinson's disease;Uso de apomorfina en la enfermedad de Parkinson

Revista de Neurologia

Volumn 35, Issue 7, 2002, Pages 668-674

  Giménez Roldán, Santiago ^a   Garcia Munozguren S ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Apomorphine; Biphasic dyskinesias; Fluctuations; Parkinson's disease

Indexed keywords

APOMORPHINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; IMMUNOGLOBULIN E; LEVODOPA; METOCLOPRAMIDE; NALOXONE; ORPHAN DRUG; SULPIRIDE;

DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SELF ADMINISTRATION; DYSKINESIA; DYSPHAGIA; HUMAN; NAUSEA; NEUROPSYCHIATRY; PARKINSON DISEASE; REVIEW; SEDATION; SELF INJECTION; SIDE EFFECT; STEREOTAXIC SURGERY; TREATMENT FAILURE; TREATMENT INDICATION; VOMITING;

EID: 0036826743     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3507.2002056     Document Type: Review

References (44)

1. Johnson AM, Loew DM, Vigouret JM. Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine (+)-amphetamine and L-Dopa. Br J Pharmacol 1976; 56: 59-68.
2. Cotzias GC, Papavasiliou PS, Fehling C, Kaufman B, Mena I. Similarities between neurologic effects of L-Dopa and apomorphine. N Engl J Med 1970; 282: 31-3.
3. Cotzias GC, Papavasiliou PS, Mendez JS, Bell-Midura M. Treatement of Parkinson's disease with apomorphine. Possible role of growth hormone. N Engl J Med 1976; 294: 567-72.
4. Gancher ST, Woodward WR, Nutt JG. Apomorphine tolerance in Parkinson's disease: lack of a dose effect. Clin Neuropharmacol 1996; 19: 59-64.
5. Ondo W, Hunter C, Almaguer M, Gancher S, Jankovic J. Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease. Clin Neuropharmacol 1999; 22: 14.
6. Broussolle E, Cinotti L, Pollak P, Landais P, Le Bars D, Galy G, et al. Relief of akinesia by apomorphine and cerebral metabolic changes in Parkinson's disease. Mov Disord 1993; 8: 459-62.
7. Grandas F, Gancher ST, Rodríguez M, Lera G, Nutt JG, Obeso JA. Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease. Clin Neuropharmacol 1992; 15: 13-8.
8. Obeso JA, Luquin NR, Grandas F, Vaamonde J, Laguna J, Martínez-Lage JM. Motor response to repeated dopaminergic stimulation in Parkinson's disease. Clin Neuropharmacol 1992; 15: 75-9.
9. Rodriguez M, Lera G, Vaamonde J, Luquin MR, Obeso JA. Motor response to apomorphine and levodopa in asymmetric Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 562-6.
10. Nutt JG, Carter JM. Apomorphine can sustain the long-duration response o L-Dopa in fluctuating Parkinson's disease. Neurology 2000; 54: 247-50.
11. Turjanski N, Fernández W, Lees A. The effect of acute levodopa withdrawal in motor performance and dopaminergic receptor sensitivity in patients wity Parkinson's disease. J Neurol Neurosurg Psychiatry 1993; 56: 771-5.
12. Vaamonde J, Luquin MR, Obeso JA. Dopaminergic responsiveness to apomorphine after chronic tratment with subcutaneous lisuride in Parkinson's disease. Mov Disord 1990; 5: 260-2.
13. Verhagen-Metman L, Locattelli ER, Bravi D, Mouradian MM, Chase TN. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 1997; 48: 369-72.
14. Barker R, Duncan J, Lees A. Subcutaneous apomorphine as a diagnostic test for dopaminergic responsiveness in parkinsonian syndromes. Lancet 1989; 1: 675.
15. Oertel WH, Gasser T, Ippish R, Trekwolder C, Poewe W. Apomorphine test for dopaminergic responsiveness. Lancet 1989; 1: 1262-3.
16. Gancher ST, Nutt JG, Woodward WR. Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance. Mov Disord 1995; 10: 34-43.
17. Bonuccelli U, Piccini P, del Dotto P, Rossi G, Corsini GU, Muratorio A. Aphomorphine test for dopaminergic responsiveness: a dose assessment study. Mov Disord 1993; 8: 158-64.
18. Linazasoro G. El test de la apomorfina en los sindromes parkinsonianos: valor diagnóstico. Neurologia 1993; 8: 288-90.
19. Linazasoro G. The apomorphine test in gait disorders associated with parkinsonism. Clin Neuropharmacol 1996; 19: 171-6.
20. Stibe CMH, Kempster PA, Lees AJ, Stern GM. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988; 1: 403-6.
21. Chaudhuri P, Crithley P, Abbott RJ, Pye IF, Millan PAH. Subcutaneous apomorphine for 'on-off' oscillations in Parkinson's disease. Lancet 1988; 2: 1260-1.
22. Mouradian MM, Heuser IJE, Baranti F, Giuffra M, Conant K, Davis TL, et al. Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991; 54: 401-5.
23. Hughes AJ, Bishop S, Kleendorfer B, Turjanski N, Fernández W, Lees AJ, et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993; 8: 165-70.
24. Przedborski S, Liard A, Hildebrand J. Induction of mania by apomorphine in a depressed parkinsonian patient. Mov Disord 1992; 7: 285-6.
25. Linazasoro G. Apomorfina subcutánea en la enfermedad de Parkinson. Neurologia 1994; 9: 1-3.
26. Steiger MJ, Quinn NP, Marsden CD. The clinical use of apomorphine un Parkinson's disease. J Neurol 1992; 239: 389-93.
27. Duriff F, Deffond D, Dordain G, Tournilhac M. Apomorphine and diphasic dyskinesias. Clin Neuropharmacol 1994; 17: 99-102.
28. Ostergaard L, Werdelin L, Odin P, Lindvall O, Dupont E, Christensen PB, et al. Pen inyected apomorphine against off phenomena in late Parkinson's disease: a double-blind, placebo-controlled study. J Neurol Neurosurg Psychiatry 1995; 58: 681-7.
29. Achard KM, Churchyard A, Fletcher C, Turner K, Lees A, Dowd PM. Panniculitis in association with apomorphine infusion. Br J Dermatol 1998; 138: 480-2.
30. Tison F, Wiart L, Guatteri M. Effects of central dopaminergic stimulation by apomorphine on swalling disorders in Parkinson's disease. Mov Disord 1996; 11: 729-32.
31. Christmas TJ, Kempster PA, Chapple CR, Frankel JP, Lees AJ, Stern GM, et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 1988; 2: 1451-3.
32. Ellis C, Lemmens G, Parkes PJ, Abbott RJ, Pye IF, Leigh PN, et al. Use of apomorphine in parkinsonian patients with neuropsychiatryc complications to oral treatment. Parkinsonism Relat Disord 1997; 3: 103-7.
33. Kempster PA, Lees AJ, Crichton P, Frankel JP, Shorvon P. Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine. Mov Disord 1989; 4: 47-52.
34. Saint-Victor J-F, Pollak P, Gervason C-L. Levodopa-induced diphasic dyskinesias improved by subcutaneous apomorphine. Mov Disord 1992; 7: 283-7.
35. Corsini GU, del Zompo M, Cianchetti C, Mangoni A. Therapeutical efficacy of a combination of apomorphine with sulpiride or metoclopramide in parkinsonism. Psychopharmacology 1976; 47: 169-73.
36. van Laar T, Janssen ENH, Essink AWG, Neef L. Intranasal apomorphine in parkinsonian fluctuations. Arch Neurol 1992; 49: 482-4.
37. Lees AJ, Montastruc JL, Turjanski N. Sublingual apomorphine and Parkinson's disease. Lancet 1990; 1: 1440.
38. Gancher ST, Nutt JG, Woodward WR. Absorption of apomorphine by various routes in parkinsonism. Mov Disord 1991; 6: 212-6.
39. Montrastruc JL, Rascol O, Senard JM, Gualano V, Boghen H, Houin G, et al. Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study. Clin Neuropharmacol 1991; 14: 432-7.
40. Van Laar T, Neef C, Danhof M, Ronki I, Roos RAC. A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease. Mov Disord 1996; 11: 633-8.
41. García-Ruiz P, Sánchez B, Vernardos V. Eficacia de la morfina intranasal y subcutánea en la enfermedad de Parkinson. Estudio comparativo agudo. Arch Neurobiol 1993; 56: 345-8.
42. van Laar T, Janssen ENH, Neef C, Danhof M, Roos RAC. Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. Mov Disord 1995; 10: 433-9.
43. Stocchi F, Farina C, Nordera G, Russien S. Implantable venous access system for apomorphine infusion in compliated Parkinson's disease. Mov Disord 1999; 14: 358-64.
44. Manson AJ, Hanagasi H, Turner K, Patsalos PN, Carry P, Lees AJ, et al. Intravenous apomorphine therapy in Parkinson's disease. Clinical and pharmakinetic observations. Brain 2001; 124: 331-40.